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Evaluating albumin utilization in a community-based hospital post-hetastarch
food and drug administration (FDA) warning
Wilbert J. Fuerte, BS, Pharm.D., Frances Ordieres, Pharm.D., Judy Tseng, Pharm.D., BCPS
South Miami Hospital, Miami, Florida

Background


Albumin is a medication commonly used in the hospital setting.



The use of albumin is not justified in every clinical situation due to the
lack of scientific evidence and the availability of other, equally effective
medications.1,2





In June of 2012, the FDA released a warning regarding an increase in
morbidity and mortality when hetastarch is used in several clinical
settings.3
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Albumin was utilized in a variety of clinical conditions, with septic shock
being the most common reason for utilization (42.5 %, N = 20).



Based on the indications described in the UHC and ATS guidelines,
albumin utilization during the time period described in this study was
appropriately used only 20.5 % of the time.



Although albumin prescribing only increased by 10.3 % after the
warning, the actual utilization of this medication increased by 47.4 %.
On the other hand, hetastarch prescribing decreased by 83.9%, while
the actual utilization of the medication decreased by 50 %.



Due to the significant increase in albumin utilization after the FDA
warning, the total expenditure due to albumin utilization increased by
39.0 %.

Surgery (Non-liver)
14.3%

Because albumin and hetastarch are colloids, overlap exists in many of
the indications of these two medications. Thus, it is expected that many
prescribers will use albumin in place of hetastarch in a variety of
clinical scenarios. Consequently, an increase in albumin utilization and
associated expenditure is expected.
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*Others refer to indications observed in the study that are not mentioned in
the UHC or ATS guidelines.

1. To identify albumin and hetastarch utilization.

N=2

N=4
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2. To evaluate if albumin is used for indications consistent with the
recommendations from the American Thoracic Society (ATS) guidelines
for the use of Colloids1 or the University Hospital Consortium (UHC)
guidelines for the use of albumin, non-protein colloids, and
crystalloids.2
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The use of albumin was considered inappropriate only if both
guidelines recommended against the use of albumin for the indication
being analyzed.



The type of surgery was not recorded unless it was a liver or cardiac
surgery.



The possibility of conditions precluding the use of normal saline were
not considered for sepsis patients.



Small sample size and study duration.
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3. To determine if the new warning against the use of hetastarch3 has
affected the prescribing pattern of albumin.
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4. To complete a cost analysis on albumin misuse.
100%

Methodology
Single-center, Baptist Health South Florida Institutional Review
Board-approved, retrospective chart review.
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¶Out of 20 patients, albumin was used after exhausting the use of
substantial amounts (≥ 4 L) of crystalloids in only 5 patients.
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†Out of the two patients, one patient received albumin for
hemodialysis-associated hypotension. The use of albumin is considered
appropriate for this use according to the ATS guideline (IIa). The other
patient received albumin 25% due to hemorrhagic hypovolemia secondary
to rectal bleeding. Both the UHC and ATS guidelines state that crystalloids
should be considered the initial resuscitation fluid of choice in this setting.

20%
10%

Study Period: September of 2012 and September of 2013.
Inclusion Criteria: All patients 18 years of age and older during the
study period for which albumin and/or hetastarch were used.



Exclusion criteria: Anyone younger than 18 years of age or who did
not use albumin or hetastarch during the study period.







A list containing the medical record number of patients for which
either albumin and/or hetastarch was used during September of 2012
and September of 2013 was obtained from the pharmacy department
system specialist.

Data Analysis:



Indication

*Out of 47 patients, 8 patients were administered albumin for an indication
not mentioned in the UHC or ATS guidelines. Thus, it is not possible to
evaluate the utilization of albumin in this subset of patients.

Descriptive statistics was completed for objectives 1, 2, and 3.
A Cost-Utility analysis was conducted for objective 4.
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Albumin Cost-Utilization Analysis

Albumin Prescribing Pattern

Patients chart were reviewed in order to collect factors of different
criteria described in the UHC and ATS guidelines for the appropriate
utilization of albumin.
Pricing was obtained from the pharmacy department buyer for cost
analysis.

‡Out of 4 patients, 2 patients received albumin 5 % which is not indicated in
the setting of liver cirrhosis unless the patient has another indication for the
medication according to either the UHC or ATS guideline.
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Although the data provided by this audit shows that prescribers are
following the FDA recommendation of minimizing the use of hetastarch,
it is concerning that albumin was appropriately utilized only 20.5 % of
the time. Based on these findings, there is an opportunity for
improvement in educating prescribers regarding the appropriate use of
albumin in order to ensure proper utilization of this medication.
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